Financials · Hospital & Medical Service Plans · NYSE · CIK 731766 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $420.57Day −1.92%Mkt cap $381.9BP/E (FY) 31.8×1Y +64.5%Off 52W high −8.8%Vol (1Y) 39.6%
Daily closing price, split-adjusted to the current basis; 3y shown of 6,679 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Fair value (model)$121.25 |
| Implied upside−71.2% |
| Valuation confidenceMEDIUM |
| Short interest1.9% of sh out |
| Days to cover3.5d |
| 13F net flow (QoQ)+1.51% |
| Top-10 13F concentration44.2% |
| Next report (est.)2026-10-20 |
Fair value, confidence and the reverse-DCF grade are the MATERIALIZED daily snapshot (the same columns the screener serves), not a live model run. Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| P/E (FY)31.8× |
| Sales (TTM)$449.71B |
| Earnings (TTM)$12.04B |
| Net margin2.7% |
| YTD+28.4% |
| 1Y+64.5% |
| 3Y−12.2% |
| 5Y+11.2% |
| 10Y+245.8% |
| Since incept. (ann.)+18.0% |
Total return through 2026-07-29 · series begins 2000-01-03. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)39.6% |
| Ann. volatility (3Y)36.7% |
| Sharpe (1Y)1.28 |
| Sharpe (3Y)0.08 |
| Max drawdown (1Y)−29.0% |
| Max drawdown (3Y)−61.4% |
| Beta (3Y vs SPY)0.74 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| BlackRock, Inc. | 73.5M | $19.9B | 8.09% | −1.7% |
| VANGUARD CAPITAL MANAGEMENT LLC | 58.9M | $15.9B | 6.49% | new |
| STATE STREET CORP | 45.3M | $12.3B | 4.99% | +0.2% |
| Capital World Investors | 27.8M | $7.5B | 3.06% | +23.0% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 24.0M | $6.5B | 2.65% | new |
| GEODE CAPITAL MANAGEMENT, LLC | 22.8M | $6.1B | 2.51% | +4.5% |
| PRICE T ROWE ASSOCIATES INC /MD/ | 20.9M | $5.6B | 2.30% | +10.9% |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 20.8M | $5.6B | 2.29% | +146.6% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-04-21 | $6.90 | +0.7% | $111.72B | +2.0% |
| 2025-12-31 | 2026-01-27 | — | — | $113.22B | +12.3% |
| 2025-09-30 | 2025-10-28 | $2.59 | −60.2% | $113.16B | +12.2% |
| 2025-06-30 | 2025-07-29 | $3.74 | −17.6% | $111.62B | +12.9% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-10-20 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Total Optum 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
| ROIC11.2% |
| Total debt / EBITDA3.36× |
| EPS growth 3Y−14.5% |
| Sales growth 3Y11.4% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
